Kyowa Hakko Kirin Co. Ltd. | Ownership
Companies that own Kyowa Hakko Kirin Co. Ltd.
Nomura Asset Management Co., Ltd.
19,836,699
3.44%
583,868
0.2%
07/31/2018
Nikko Asset Management Co., Ltd.
7,665,824
1.33%
125,624
0.08%
09/03/2018
Daiwa Asset Management Co. Ltd.
6,745,100
1.17%
-97,199
0.14%
07/31/2018
Wellington Management Co. LLP
6,235,379
1.08%
29,069
0.02%
07/31/2018
The Vanguard Group, Inc.
6,221,413
1.08%
15,600
0%
07/31/2018
Norges Bank Investment Management
4,335,499
0.75%
229,962
0.01%
12/31/2017
BlackRock Fund Advisors
4,200,900
0.73%
-3,100
0%
09/06/2018
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.
3,722,316
0.65%
1,916
0.14%
07/31/2018
T. Rowe Price Associates, Inc.
2,139,900
0.37%
2,139,900
0.01%
06/30/2018
OppenheimerFunds, Inc.
1,816,200
0.32%
0
0.02%
02/28/2018
| Address |
Otemachi Financial City Grand Cube
Tokyo Tokyo 100
Japan
|
|
Employees
|
- |
| Website |
http://www.kyowa-kirin.co.jp |
| Updated |
07/08/2019 |
| Kyowa Hakko Kirin Co., Ltd. engages in the manufacture and sale of medical and pharmaceutical products. It operates through the Pharmaceuticals and Bio-Chemicals segments. The Pharmaceuticals segment deals with the research, development, production, and sale of in vitro diagnostic reagents and ethical drugs concerning renal anemia, leukemia, cancer, allergies, and hypertension. |
